Abstract Details
Activity Number:
|
100
|
Type:
|
Invited
|
Date/Time:
|
Monday, August 5, 2013 : 8:30 AM to 10:20 AM
|
Sponsor:
|
Section for Statistical Programmers and Analysts
|
Abstract - #307233 |
Title:
|
Open Source and Commercialized Open Source: Risks, Mitigations, and Upsides for Commercial Regulated R&D
|
Author(s):
|
Anthony Joseph Rossini and Vincent Carey*+
|
Companies:
|
Novartis Pharma AG and Harvard Medical School
|
Keywords:
|
Open Source ;
statistical practice ;
pharmaceutical R&D ;
computer systems validation ;
software ;
data analysis
|
Abstract:
|
Software, whether open source or commercial, needs to be assessed for the risk that it introduces to business processes. "open source" describes a license model, not a risk mitigation model. With the increasingly recognized (by non-statisticians) of the importance of statistical input and thinking, this input introduces, in addition to tremendous benefits, risks surrounding the "process of statistical analysis", which includes statistical software selection. We discuss issues surrounding statistical software selection, impact on the form and quality of the "process of statistical analysis". This is a critical but often downgraded aspect of "Statistical Practice", and we hope to provide clarity on this issue and justify why it requires careful consideration as the "process of statistical analysis" evolves from an early young (and being evaluated) to a mature stage and an essential (and streamlined) business process.
|
Authors who are presenting talks have a * after their name.
Back to the full JSM 2013 program
|
2013 JSM Online Program Home
For information, contact jsm@amstat.org or phone (888) 231-3473.
If you have questions about the Continuing Education program, please contact the Education Department.
The views expressed here are those of the individual authors and not necessarily those of the JSM sponsors, their officers, or their staff.
Copyright © American Statistical Association.